Patents Assigned to MindImmune Therapeutics, Inc.
  • DENDRITIC CELL RECRUITMENT FROM BLOOD TO BRAIN IN NEURODEGENERATIVE DISEASE
    Publication number: 20210181185
    Abstract: The present disclosure provides methods of treating neurodegenerative diseases, including administering agents that block dendritic cells from entering the brain from the blood. The present further describes methods for detecting the selective migration of dendritic cells from blood into brain as a marker of human neurodegenerative disease. The present disclosure further describes methods that can be used to evaluate and compare different embodiments of methods detecting migration of dendritic cells using transgenic mice that overexpress various mutations associated with induction of distinct neurodegenerative disease pathologies.
    Type: Application
    Filed: November 8, 2018
    Publication date: June 17, 2021
    Applicant: MindImmune Therapeutics, Inc.
    Inventors: Brian Michael Campbell, Frank Samuel Menniti, Robert Brelsford Nelson, Stevin Howard Zorn
  • Benzamides-containing compounds and their use in the treatment of epilepsy
    Patent number: 10238654
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of epilepsy.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 26, 2019
    Assignee: MINDIMMUNE THERAPEUTICS, INC.
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • Cyclic amines
    Patent number: 10124010
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 13, 2018
    Assignee: MindImmune Therapeutics, Inc.
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang